UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000019754
Receipt number R000022813
Scientific Title Clinical and prognostic significance of pathological reclassification in ovarian neuroendocrine tumors: a retrospective study (O-NET study)
Date of disclosure of the study information 2015/11/11
Last modified on 2020/05/15 20:25:02

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Clinical and prognostic significance of pathological reclassification
in ovarian neuroendocrine tumors: a retrospective study (O-NET study)

Acronym

Clinical and prognostic significance of pathological reclassification
in ovarian neuroendocrine tumors: a retrospective study (O-NET study)

Scientific Title

Clinical and prognostic significance of pathological reclassification
in ovarian neuroendocrine tumors: a retrospective study (O-NET study)

Scientific Title:Acronym

Clinical and prognostic significance of pathological reclassification
in ovarian neuroendocrine tumors: a retrospective study (O-NET study)

Region

Japan


Condition

Condition

Primary ovarian neuroendocrine tumors

Classification by specialty

Obstetrics and Gynecology

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

To validate the versatility of the novel WHO 2010 classification for gastrointestinal neuroendocrine tumors to the primary ovarian neuroendocrine tumors.

Basic objectives2

Others

Basic objectives -Others

We retrospectively classified ovarian neuroendocrine tumors according to the novel WHO 2010 classification for gastrointestinal neuroendocrine tumors.

Trial characteristics_1

Confirmatory

Trial characteristics_2


Developmental phase

Not applicable


Assessment

Primary outcomes

Overall survival time

Key secondary outcomes

Progression free survival time


Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit


Not applicable

Age-upper limit


Not applicable

Gender

Female

Key inclusion criteria

Patients with pathologically diagnosis of primary ovarian neuroendocrine tumor for the periods from 1995 to 2014.

Key exclusion criteria

Multiple malignancies within five years.

Target sample size

30


Research contact person

Name of lead principal investigator

1st name Kentaro
Middle name
Last name Kai

Organization

Oita University Faculty of Medinice

Division name

Department of Obstetrics and Gynecology

Zip code

879-5593

Address

1-1 Idaigaoka, Hasama-machi, Yufu City, Oita 879-5593, Japan

TEL

097-586-5922

Email

kenta9sp@oita-u.ac.jp


Public contact

Name of contact person

1st name Kentaro
Middle name
Last name Kai

Organization

Oita University Faculty of Medicine

Division name

Department of Obstetrics and Gynecology

Zip code

879-5593

Address

1-1 Idaigaoka, Hasama-machi, Yufu City, Oita 879-5593, Japan

TEL

097-586-5922

Homepage URL


Email

kenta9sp@oita-u.ac.jp


Sponsor or person

Institute

Kansai Clinical Oncology Group - Gynecologic Cancer Group -

Institute

Department

Personal name



Funding Source

Organization

Kansai Clinical Oncology Group - Gynecologic Cancer Group -

Organization

Division

Category of Funding Organization

Non profit foundation

Nationality of Funding Organization

Japan


Other related organizations

Co-sponsor

SGSG (Sankai Gynecology Study Gruop), TGCU (Tohoku Gynecologic Cancer Unit), GOTIC (Gynecologic Oncology Trial and Investigation Consortium of North Kanto), GOGO (Gynecologic Oncology Gruop of Osaka), WJGOG (Weas Japan Gynecologic Oncology Gruop)

Name of secondary funder(s)



IRB Contact (For public release)

Organization

Institutional Review Board of Oita University Faculty of Medicine (1st General Affairs Division)

Address

1-1 Idaigaoka, Hasama-machi, Yufu City, Oita 879-5593, Japan

Tel

097-586-5120

Email

syomu@oita-u.ac.jp


Secondary IDs

Secondary IDs

YES

Study ID_1

KCOG-G1502s

Org. issuing International ID_1

Kansai Clinical Oncology Group - Gynecologic Cancer Group -

Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

大分大学病院(大分県)


Other administrative information

Date of disclosure of the study information

2015 Year 11 Month 11 Day


Related information

URL releasing protocol

http://www.med.oita-u.ac.jp/sanka/patient/index6.html

Publication of results

Published


Result

URL related to results and publications

https://www.karger.com/Article/Abstract/506743

Number of participants that the trial has enrolled

48

Results

Of the 68 enrolled patients, 48 were eligible for analysis. All carcinoids (n = 32) were reclassified as NET G1/G2, whereas 14 of 16 carcinomas were reclassified as NEC/mixed adeno-NEC (MANEC) (Fisher exact test; p < 0.01). The OS/PFS was 49.0/42.5 months and 6.5/3.9 months for NET G1/G2 and NEC/MANEC, respectively. Histology revealed that NEC/MANEC was associated with increased risk of death (HR = 48.0; 95% CI, 3.93-586; p < 0.01) and disease progression (HR = 51.6; 95% CI, 5.54-480; p < 0.01).

Results date posted

2020 Year 05 Month 15 Day

Results Delayed

Delay expected

Results Delay Reason

Longer period needed than our expectation for central pathological review.

Date of the first journal publication of results

2020 Year 02 Month 25 Day

Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Main results already published

Date of protocol fixation

2015 Year 07 Month 24 Day

Date of IRB

2015 Year 06 Month 16 Day

Anticipated trial start date

2015 Year 11 Month 11 Day

Last follow-up date

2017 Year 08 Month 30 Day

Date of closure to data entry

2017 Year 08 Month 30 Day

Date trial data considered complete

2018 Year 05 Month 17 Day

Date analysis concluded

2018 Year 10 Month 11 Day


Other

Other related information

We retrospectively classified ovarian neuroendocrine tumors according to the novel WHO 2010 classification for gastrointestinal neuroendocrine tumors to evaluate the prognostic value of the WHO 2010 classification in ovarian neuroendocrine tumors.


Management information

Registered date

2015 Year 11 Month 11 Day

Last modified on

2020 Year 05 Month 15 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000022813


Research Plan
Registered date File name
2017/05/13 KCOG-G1502s_卵巣がん研究_実施計画書v1.5.doc

Research case data specifications
Registered date File name

Research case data
Registered date File name